# Cancer Biology Program - 01

> **NIH NIH P30** · JOHNS HOPKINS UNIVERSITY · 2020 · $36,924

## Abstract

ABSTRACT
The Sidney Kimmel Comprehensive Cancer Center (SKCCC) Cancer Biology (CB) Program's overall goal is to
understand the cellular and molecular alterations that drive human tumorigenesis and to exploit the
translational potential of this information for cancer diagnosis, therapy and prevention. The translational
mission was accentuated in the current cycle through the addition of Program members with expertise in
developing clinical trials, translating findings from the Program. The Program has been part of the CCSG for
over 25 years and is composed of 39 SKCCC faculty members representing eight departments of the School
of (Medicine, Oncology, Otolaryngology–Head and Neck Surgery, Pathology, Radiation Oncology and
Molecular Radiation Sciences, Surgery, Molecular Biology and Genetics, Biophysics and Biophysical
Chemistry), one from the Bloomberg School of Public Health (Biochemistry and Molecular Biology) and two
from the Whiting School of Engineering (Biomedical Engineering, Mechanical Engineering). Faculty members
hold appointments in five different graduate programs in the School of Medicine (Cellular and Molecular
Medicine, Human Genetics and Molecular Biology, Biochemistry and Molecular Biology, Pharmacology, and
Pathobiology) and one in the Bloomberg School of Public Health (Biochemistry and Molecular Biology). The
Program is supported by $21 million in NCI and other peer-reviewed support and has 835 total publications—
228 (27%) are Intra-Programmatic, 327 (38%) are Inter-Programmatic and 317 (38%) were multi-institutional
collaborations. Virtually all faculty members are housed in the SKCCC Research Complex Buildings, and there
are more than 20 graduate students and over 60 Postdoctoral research fellows in the Program. Under the
direction of Stephen Baylin, M.D., and Victor Velculescu, M.D., Ph.D., the specific aims of the CB Program are:
Aim 1. To define genetic abnormalities that drive human cancer initiation and progression. Program members
will continue to define the basic function of the genes and molecular mechanisms underlying human cancer,
particularly those that may be amenable to therapeutic or diagnostic intervention.
Aim 2. To define the molecular origins of epigenetic changes that underlie tumor initiation and progression and
the signaling events they control, and harness this information to design therapeutic strategies and devise
biomarker strategies.
Aim 3. To translate basic and preclinical findings to investigator-initiated clinical trials led by CB Program
members and members of other Programs throughout the SKCCC. The basic research in the Program has
increasing translational significance that will continue to move to clinical testing by highly Inter-Programmatic
teams in the areas of molecular marker strategies for cancer risk assessment, diagnosis and prognosis, and
new strategies for cancer treatment and prevention.
Members contribute significantly to the GI, Head and Neck, and Prostate SPOREs, and the leader ...

## Key facts

- **NIH application ID:** 9944512
- **Project number:** 5P30CA006973-57
- **Recipient organization:** JOHNS HOPKINS UNIVERSITY
- **Principal Investigator:** STEPHEN B. BAYLIN
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $36,924
- **Award type:** 5
- **Project period:** — → —

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9944512

## Citation

> US National Institutes of Health, RePORTER application 9944512, Cancer Biology Program - 01 (5P30CA006973-57). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/9944512. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*